Similarly, miR-520b promoted doxorubicin sensitivity in breast cancer cells through downregulation of IGF-1R, i.e., abrogating tumor development, metastasis, and resistance to chemotherapy induced by IGF-1R (38). This evidence concerns the gene IGF1R and breast carcinoma.